On May 31, 2026 Precede Biosciences, a company powering next-generation precision medicine through its functional liquid biopsy platform, reported two new data presentations at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held May 29 to June 2 in Chicago, Illinois.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data highlight how functional information beyond genomics in patients with advanced non-small cell lung cancer (NSCLC), including target expression, pathway activity, and cell-state changes associated with response and resistance to targeted therapies, can be revealed from only 1 mL of plasma using Precede Bio Insight.
"Patients with advanced NSCLC in whom MET is an important disease driver often require multiple lines of therapy, underscoring the need to better understand the biology driving response and resistance," said J. Carl Barrett, PhD, Chief Scientific Officer of Precede Biosciences. "For drug developers working to advance MET-targeted therapies, these data demonstrate the ability of our platform to provide a broad functional view of tumor biology from plasma that can help guide patient selection and rational therapeutic development strategies."
ASCO 2026 Presentations
Comprehensive Epigenomic Profiling of Plasma for Non-invasive Detection of MET Activation Uncovers MET-associated Biology in Patients with EGFR-mutated Advanced NSCLC and Progression on Osimertinib (Abstract 8642)
Plasma Epigenomic Profiling Identifies Mechanisms of Sensitivity and Resistance to Tepotinib in METex14 Skipping Metastatic NSCLC (Abstract 8637)
(Press release, Precede Biosciences, MAY 31, 2026, View Source [SID1234666285])